Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck
- PMID: 16036307
- DOI: 10.1080/10611860500065187
Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck
Abstract
Human squamous cell carcinoma of the head and neck (SCCHN) is characterized by over expression of a tumor cell surface-specific receptor namely Hsp47/CBP2 that makes it a favorable candidate for targeted delivery of anticancer drugs. Several synthetic peptides have been identified as effective ligands for binding to CBP2. The purpose of this study is to investigate the potential of water-soluble N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin (Dox) conjugates containing a Hsp47/CBP2 binding peptide sequence, namely WHYPWFQNWAMA for targeted delivery to SCCHN. An HPMA copolymer containing Dox and CBP2 targeting peptide conjugated via lysosomally degradable glycylphenylalanylleucylglycine (GFLG) spacer was synthesized by free radical precipitation copolymerization. A control polymer without targeting moiety was also synthesized. The conjugates were characterized for drug content, peptide content, molecular weight and molecular weight distribution. The uptake of polymeric conjugates by both drug resistant and drug sensitive SCCHN cells were determined in vitro by flow cytometry using FACS scan analysis. Cytotoxicity of the conjugates towards drug sensitive as well as multidrug resistant SCCHN cells were evaluated by a clonal survival assay and compared to free Dox. The cytotoxicity of the free peptide was similarly evaluated. The internalization and subcellular fate of the conjugates in drug sensitive SCCHN cells was monitored using confocal microscopy. The new targetable copolymer contained 0.16 mmole peptide/g polymer. Studies on drug sensitive SCCHN cells demonstrated lesser uptake of both targeted and non-targeted conjugates compared to free Dox suggesting a slower endocytic mechanism of uptake for the conjugates as opposed to rapid diffusion of free Dox. At higher Dox equivalent concentrations (>20 microM) the targeted conjugate showed significantly higher uptake (p < or = 0.028) than the non-targeted conjugate. The uptake of the targeted conjugate was inhibited in the presence of an anti Hsp47 antibody suggesting the involvement of active receptor mediated endocytosis in cell entry of the conjugate. Compared to free Dox, the targeted and non-targeted conjugates caused marginally lower inhibition (p < or = 0.01) of the drug sensitive SCCHN cells. In contrast, the same conjugates showed significantly higher uptake (p < or = 0.004) by drug resistant SCCHN cells and caused significantly higher inhibition (p < or = 0.02) of drug resistant SCCHN cells when compared to free Dox. Results suggest that the polymeric conjugates were able to overcome drug resistance. Confocal microscopy studies demonstrated the uptake of the polymeric conjugates, followed by internalization, intralysosomal localization and subsequent release of Dox. HPMA copolymer-Dox-peptide conjugates targeted to SCCHN cells were able to overcome drug resistance and increase efficacy in vitro. The results suggest that targetable polymeric conjugates have potential to improve systemic head and neck cancer chemotherapy by increasing tumor localization and reducing dose-limiting toxicity.
Similar articles
-
Synthesis and in vitro anti-tumor activity of novel HPMA copolymer-drug conjugates with potential cell surface targeting property for carcinoma cells.Eur J Pharm Biopharm. 2012 Feb;80(2):379-86. doi: 10.1016/j.ejpb.2011.10.020. Epub 2011 Nov 12. Eur J Pharm Biopharm. 2012. PMID: 22101181
-
Targeting of human squamous carcinomas by SPA470-doxorubicin immunoconjugates.J Drug Target. 2003 Feb;11(2):101-7. doi: 10.1080/1061186031000121478. J Drug Target. 2003. PMID: 12881196
-
Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.Pharm Res. 2002 Apr;19(4):396-402. doi: 10.1023/a:1015170907274. Pharm Res. 2002. PMID: 12033370
-
Designing polymer conjugates as lysosomotropic nanomedicines.Biochem Soc Trans. 2007 Feb;35(Pt 1):56-60. doi: 10.1042/BST0350056. Biochem Soc Trans. 2007. PMID: 17233601 Review.
-
Cytoplasmic delivery and nuclear targeting of synthetic macromolecules.J Control Release. 2003 Feb 21;87(1-3):89-105. doi: 10.1016/s0168-3659(02)00352-8. J Control Release. 2003. PMID: 12618026 Review.
Cited by
-
Design of smart HPMA copolymer-based nanomedicines.J Control Release. 2016 Oct 28;240:9-23. doi: 10.1016/j.jconrel.2015.10.003. Epub 2015 Oct 3. J Control Release. 2016. PMID: 26437260 Free PMC article. Review.
-
Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of alpha(v)beta(6)-positive cancers.Bioconjug Chem. 2008 Sep;19(9):1813-21. doi: 10.1021/bc800154f. Epub 2008 Aug 19. Bioconjug Chem. 2008. PMID: 18710273 Free PMC article.
-
The heat shock protein 47 as a potential biomarker and a therapeutic agent in cancer research.J Cancer Res Clin Oncol. 2018 Dec;144(12):2319-2328. doi: 10.1007/s00432-018-2739-9. Epub 2018 Aug 20. J Cancer Res Clin Oncol. 2018. PMID: 30128672 Free PMC article. Review.
-
Peptide-based Biopolymers in Biomedicine and Biotechnology.Mater Sci Eng R Rep. 2008 Jan;62(4):125-155. doi: 10.1016/j.mser.2008.04.004. Mater Sci Eng R Rep. 2008. PMID: 19122836 Free PMC article.
-
Preparation, drug release, and cell growth inhibition of a gelatin: doxorubicin conjugate.Pharm Res. 2013 Aug;30(8):2087-96. doi: 10.1007/s11095-013-1065-9. Epub 2013 May 18. Pharm Res. 2013. PMID: 23686374 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous